Androgel, Testosterone Lawsuits Under Investigation by Morgan & Morgan

Share Article

As the FDA reassesses the safety of prescription testosterone therapies, Morgan & Morgan is investigating potential lawsuits on behalf of men who suffered heart attacks or strokes while using these products.

"We believe men across the country were drawn to or prescribed these products without being given proper warning to their potential side effects."

The attorneys at Morgan & Morgan are investigating potential lawsuits on behalf of men who used AndroGel or other prescription testosterone products and suffered from heart attacks, strokes or other life-threatening cardiac or thrombolytic events. Only days after the FDA announced* a probe into the safety of these treatments, the maker of AndroGel, a popular prescription testosterone gel, was hit with five lawsuits** claiming that it downplayed the health risks associated with use of the product, court documents state.

"We believe men across the country were drawn to or prescribed these products without being given proper warning to their potential side effects," said Laura Yaeger, an attorney in Morgan & Morgan's mass tort department. "We plan on investigating what the makers of Androgel and other 'low t' therapies knew and when exactly they were aware of the products' possible heart risks.”

On Jan. 31, 2014, the FDA announced* that it would be evaluating the risk of stroke, heart attack and death in men using agency-approved testosterone products. The agency made this announcement following the publication of two separate studies suggesting that men using prescription testosterone therapies may be at an increased risk for cardiovascular events. The first study reviewed by the FDA was published in the Journal of the American Medical Association on November 5, 2013*** and suggested that men using prescription testosterone therapies had a 30 percent increased risk of death, stroke and heart attack when compared to men not using the products. The second study, which was published in the journal PLoS One on January 29, 2014,**** examined the rate of heart attacks in 56,000 older and middle-aged men in the year prior to beginning testosterone therapy and in the three months after starting use. According to the study, men ages 65 and older, as well as middle-aged men with a history of heart disease, had twice the rate of heart attacks in the months after starting testosterone therapy.

Products used to treat “low T” have come under increasing scrutiny among some scientists and industry experts who believe that the drugs have been marketed and sold to men who may not need them, according to a Nov. 2013 article published in the New York Times.***** The Times reports that sales of testosterone products, which include gels, patches and injections, soared to approximately $2 billion in 2012. In its announcement, the FDA reminded the public that these products are only approved for use in men with low testosterone levels in connection with an associated medical condition.

For more information on Morgan & Morgan’s investigation and to receive a free online consultation, please visit today.

About Morgan & Morgan

Morgan & Morgan is one of the largest exclusively plaintiffs’ law firms in the country with 15 offices throughout Florida, Georgia, Mississippi, Tennessee, and New York. The firm handles cases nationally involving personal injury, medical malpractice, consumer class action, and securities fraud, as well as complex litigation against drug and medical device manufacturers. Visit Morgan & Morgan online at for a free case evaluation and information about your legal rights.


**Case number 1:14-cv-00772; case number 1:14-cv-00774; case number 1:14-cv-00776; case number 1:14-cv-00777; case number 1:14-cv-00780, all in the U.S. District Court for the Northern District of Illinois. These actions were not filed by Morgan & Morgan.




Share article on social media or email:

View article via:

Pdf Print

Contact Author

Laura Yaeger
Visit website